Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study

English version České info

Combination antiretroviral therapy (cART) reduces HIV-associated morbidities and mortalities but cannot cure the infection. Given the difficulty of eradicating HIV-1, a functional cure for HIV-infected patients appears to be a more reachable short-term goal. We identified 14 HIV patients (post-treatment controllers [PTCs]) whose viremia remained controlled for several years after the interruption of prolonged cART initiated during the primary infection. Most PTCs lacked the protective HLA B alleles that are overrepresented in spontaneous HIV controllers (HICs); instead, they carried risk-associated HLA alleles that were largely absent among the HICs. Accordingly, the PTCs had poorer CD8+ T cell responses and more severe primary infections than the HICs did. Moreover, the incidence of viral control after the interruption of early antiretroviral therapy was higher among the PTCs than has been reported for spontaneous control. Off therapy, the PTCs were able to maintain and, in some cases, further reduce an extremely low viral reservoir. We found that long-lived HIV-infected CD4+ T cells contributed poorly to the total resting HIV reservoir in the PTCs because of a low rate of infection of naïve T cells and a skewed distribution of resting memory CD4+ T cell subsets. Our results show that early and prolonged cART may allow some individuals with a rather unfavorable background to achieve long-term infection control and may have important implications in the search for a functional HIV cure.

Vyšlo v časopise: Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS Pathog 9(3): e32767. doi:10.1371/journal.ppat.1003211
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003211

Souhrn

Zdroje

1. Antiretroviral-Therapy-Cohort-Collaboration (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293–299.

2. WongJK, HezarehM, GunthardHF, HavlirDV, IgnacioCC, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291–1295.

3. BongiovanniM, CasanaM, TincatiC, d'Arminio MonforteA (2006) Treatment interruptions in HIV-infected subjects. J Antimicrob Chemother 58: 502–505.

4. CainLE, LoganR, RobinsJM, SterneJA, SabinC, et al. (2011) When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 154: 509–515.

5. YerlyS, KaiserL, PernegerTV, ConeRW, OpravilM, et al. (2000) Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 14: 243–249.

6. DelwartE, MagierowskaM, RoyzM, FoleyB, PeddadaL, et al. (2002) Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS 16: 189–195.

7. Ngo-Giang-HuongN, DeveauC, Da SilvaI, PellegrinI, VenetA, et al. (2001) Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 15: 665–673.

8. AlterG, TeigenN, DavisBT, AddoMM, SuscovichTJ, et al. (2005) Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 106: 3366–3369.

9. MoirS, BucknerCM, HoJ, WangW, ChenJ, et al. (2010) B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 116: 5571–5579.

10. OxeniusA, PriceDA, EasterbrookPJ, O'CallaghanCA, KelleherAD, et al. (2000) Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A 97: 3382–3387.

11. HechtFM, WangL, CollierA, LittleS, MarkowitzM, et al. (2006) A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 194: 725–733.

12. RosenbergES, AltfeldM, PoonSH, PhillipsMN, WilkesBM, et al. (2000) Immune control of HIV-1 after early treatment of acute infection. Nature 407: 523–526.

13. SengR, GoujardC, DesquilbetL, SinetM, RouziouxC, et al. (2008) Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts). J Acquir Immune Defic Syndr 49: 251–258.

14. KaufmannDE, LichterfeldM, AltfeldM, AddoMM, JohnstonMN, et al. (2004) Limited durability of viral control following treated acute HIV infection. PLoS Med 1: e36.

15. HocquelouxL, PrazuckT, Avettand-FenoelV, LafeuilladeA, CardonB, et al. (2010) Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 24: 1598–1601.

16. GoujardC, ChaixML, LambotteO, DeveauC, SinetM, et al. (2009) Spontaneous control of viral replication during primary HIV infection: when is “HIV controller” status established? Clin Infect Dis 49: 982–986.

17. PereyraF, JiaX, McLarenPJ, TelentiA, de BakkerPI, et al. (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330: 1551–1557.

18. BoufassaF, Saez-CirionA, LechenadecJ, ZucmanD, Avettand-FenoelV, et al. (2011) CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory. PLoS ONE 6: e18726 doi:10.1371/journal.pone.0018726

19. MiguelesSA, SabbaghianMS, ShupertWL, BettinottiMP, MarincolaFM, et al. (2000) HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 97: 2709–2714.

20. AlizadehM, GagneK, MoineA, BignonJD, BensaJC, et al. (2008) Evidence for the improvement of French Volunteer Bone Marrow Donor Registry by using HLA-SBT at the registration step. Tissue Antigens 71: 315.

21. GaoX, NelsonGW, KarackiP, MartinMP, PhairJ, et al. (2001) Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. The New England journal of medicine 344: 1668–1675.

22. Saez-CirionA, LacabaratzC, LambotteO, VersmisseP, UrrutiaA, et al. (2007) HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 104: 6776–6781.

23. Gea-BanaclocheJC, MiguelesSA, MartinoL, ShupertWL, McNeilAC, et al. (2000) Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol 165: 1082–1092.

24. DoisneJM, UrrutiaA, Lacabaratz-PorretC, GoujardC, MeyerL, et al. (2004) CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol 173: 2410–2418.

25. HuntPW, BrenchleyJ, SinclairE, McCuneJM, RolandM, et al. (2008) Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 197: 126–133.

26. Saez-CirionA, HamimiC, BergamaschiA, DavidA, VersmisseP, et al. (2011) Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood 118: 955–964.

27. LewinSR, RouziouxC (2011) HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 25: 885–897.

28. ChomontN, DaFonsecaS, VandergeetenC, AncutaP, SekalyRP (2011) Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Current opinion in HIV and AIDS 6: 30–36.

29. DescoursB, Avettand-FenoelV, BlancC, SamriA, MelardA, et al. (2012) Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 54: 1495–1503.

30. LodiSMLKAD, et al. (2012) Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to hiv seroconversion. Archives of Internal Medicine 172(16): 1252–1255.

31. GoujardC, GiraultI, RouziouxC, LecurouxC, DeveauC, et al. (2012) HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antiviral therapy 17: 1001–1009.

32. OkuliczJF, MarconiVC, LandrumML, WegnerS, WeintrobA, et al. (2009) Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 200: 1714–1723.

33. HuangJ, GoedertJJ, SundbergEJ, CungTD, BurkePS, et al. (2009) HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses. J Exp Med 206: 2959–2966.

34. Saez-CirionA, SinetM, ShinSY, UrrutiaA, VersmisseP, et al. (2009) Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol 182: 7828–7837.

35. EmuB, SinclairE, HatanoH, FerreA, ShacklettB, et al. (2008) HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 82: 5398–5407.

36. MadecY, BoufassaF, PorterK, MeyerL (2005) Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 19: 2001–2007.

37. StrainMC, LittleSJ, DaarES, HavlirDV, GunthardHF, et al. (2005) Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 191: 1410–1418.

38. ChunTW, JustementJS, MurrayD, HallahanCW, MaenzaJ, et al. (2010) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24: 2803–2808.

39. GanesanA, ChattopadhyayPK, BrodieTM, QinJ, GuW, et al. (2010) Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis 201: 272–284.

40. BrenchleyJM, HillBJ, AmbrozakDR, PriceDA, GuenagaFJ, et al. (2004) T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 78: 1160–1168.

41. PaiardiniM, CervasiB, Reyes-AvilesE, MicciL, OrtizAM, et al. (2011) Low levels of SIV infection in sooty mangabey central memory CD(4)(+) T cells are associated with limited CCR5 expression. Nature medicine 17: 830–836.

42. BeaumierCM, HarrisLD, GoldsteinS, KlattNR, WhittedS, et al. (2009) CD4 downregulation by memory CD4+ T cells in vivo renders African green monkeys resistant to progressive SIVagm infection. Nat Med 15: 879–885.

43. AssomouL, DescampsD, YerlyS, Dos SantosG, MarcelinAG, et al. (2010) Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/ml in 2009: a French nationwide study. Antiviral Therapy 15: A185–A185.

44. CohenMS, ChenYQ, McCauleyM, GambleT, HosseinipourMC, et al. (2011) Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med 365: 493–505.

45. Saez-CirionA, ShinSY, VersmisseP, Barre-SinoussiF, PancinoG (2010) Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses. Nat Protoc 5: 1033–1041.

46. Avettand-FenoelV, ChaixML, BlancheS, BurgardM, FlochC, et al. (2009) LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 81: 217–223.

47. Avettand-FenoelV, PrazuckT, HocquelouxL, MelardA, MichauC, et al. (2008) HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS 22: 1880–1882.